53% clearance rate, 100 no result, 40 not reported and a few withdrawn.Could break 50% first time in a long time once all data through.Economy and global concerns weighing on buyers says REIV.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%
